IVI Appoints Dr. Richard Chapman as Chief Scientific Officer
Summary
Sam Nussbaum, MD, IVI’s Board of Directors President and former Chief Medical Officer for Anthem, said: “As value assessment becomes an underpinning of U.S. health policy and decision-making, scientific testing and validation of models and methods become increasingly important. I’m looking forward to helping IVI apply its patient-centric and transparent approach to additional disease-state models.” Chapman holds a PhD in health policy with a concentration in decision sciences from Harvard University. Alexandria, VA, January 26, 2021 --( PR.com )-- The Innovation and Value Initiative (IVI) – a nonprofit organization dedicated to advancing the science, practice, and use of value assessment in healthcare – today announced that Rick Chapman, PhD, will be its next Chief Scientific Officer. “His wealth of health economics and outcomes research experience will guide IVI’s contributions to research and methods that ensure patient-centricity, transparency, and flexibility in economic modeling and value assessment.”At ICER, Chapman led the development of economic evaluations that accompanied rigorous reviews of clinical evidence, including the assessment of potential costs, cost-effectiveness, and budgetary impact of a wide range of diagnostic, prognostic, therapeutic, and other clinical interventions.Sam Nussbaum, MD, IVI’s Board of Directors President and former Chief Medical Officer for Anthem, said: “As value assessment becomes an underpinning of U.S. health policy and decision-making, scientific testing and validation of models and methods become increasingly important. I’m looking forward to helping IVI apply its patient-centric and transparent approach to additional disease-state models.”Chapman holds a PhD in health policy with a concentration in decision sciences from Harvard University.